Back to Trials
NCT06647134Recruiting

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

M.D. Anderson Cancer Center

Start Date

9/11/2024

Completion Date

3/31/2028

Summary

To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.

Detailed Description

1. To understand the severity and nature of participants experiences during rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy, including their functional impact 2. To explore domains relevant to participants experiencing rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy, and attitudes to domains identified from the literature

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria The criteria are: * Patients aged 18 years and above * English (conversational level) speaking, with the ability to give informed consent * Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy Exclusion Criteria * Acutely life-threatening or worsening cancer * Hearing impairment functionally limiting participation in verbal interview

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

ArthritisPolymyalgia RheumaticaImmune Checkpoint Inhibitors

Locations

MD Anderson Cancer Center

Houston, Texas 77030

United States